Keywords

corticosteroid, drug approvals, FDA, HIV, multiple sclerosis, narcolepsy, new drugs, obstructive sleep apnea, osteoporosis, postpartum depression, psoriasis

Authors

1. Crump, Lauren Hartsell PharmD
2. Benfield, Miranda PharmD
3. Ramey, Caleb
4. Arcara, Ashley BS
5. Yang, Sebin BA
6. Brown, Jenna BS
7. Mospan, Geoffrey PharmD, BCPS
8. Mospan, Cortney PharmD, BCACP, BCGP

Abstract

Abstract: In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol (Duaklir Pressair); and siponimod (Mayzent).